NCT04406623View on ClinicalTrials.gov

Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

February 2, 2023

Study Completion Date

February 2, 2023

Conditions
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Interventions
DRUG

SL-172154

The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.

Trial Locations (6)

27599

University of North Carolina at Chapel Hill, Chapel Hill

37203

Sarah Cannon Research Institute, Nashville

49546

START Midwest, Grand Rapids

73104

Stephenson Cancer Center at Oklahoma University, Oklahoma City

84119

START Mountain Region, West Valley City

91016

City of Hope, Duarte

All Listed Sponsors
lead

Shattuck Labs, Inc.

INDUSTRY

NCT04406623 - Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | Biotech Hunter | Biotech Hunter